Uncategorized

September9, 2022- Today, the U.S. Food and Drug Administration approved SOTYKTU (Deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. “Based on its ability to improve skin clarity shown in the POETYK PSO clinical trials, Sotyktu (Deucravacitinib) has the potential to set a new benchmark as […]

The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended, as the FDA has approved the first drug for the fatty liver disease. After a long and winding drug development path for the common disease, Madrigal Pharmaceuticals’ resmetirom, to be sold under the brand name Rezdiffra, has become the first MASH